Relapse: Clinical Trials

3 trials for Relapse, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 terminated. 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 23Terminated 3

Follow Relapse: new trials by email Literature Review of Relapse trials Research Report on Relapse

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
HIgh Dose Thymoglobulin Instead of Cyclosporine With a Low Dose of Thymoglobulin for GVHD Prophylaxis
Treatment Arm - high dose ATG, Control Arm - standard of care - Graft-versus-host-disease, Relapse
Phase 2TerminatedAHS Cancer Control Alberta682020-07-012025-07-18
ASCT for Relapsed APL After Molecular Remission
autologous hematopoietic cell transplantation - Acute Promyelocytic Leukemia, Relapse
Phase 2TerminatedShanghai Jiao Tong University School of Medicine52009-06-012014-12-02
Efficacy of Topotecan and Lapatinib in Early Recurrent Ovarian or Peritoneal Cancer
TOPOTECAN, LAPATINIB - Cancer, Ovarian
Phase 2TerminatedCentre Francois Baclesse392008-03-012009-04-28

Narrower conditions

Recurrence (3)  ·  Graft vs Host Disease (1)  ·  Leukemia, Promyelocytic, Acute (1)  ·  Neoplasms (1)

Broader conditions

Disease Attributes (3)  ·  Pathologic Processes (3)  ·  Pathological Conditions, Signs and Symptoms (3)  ·  Hematologic Diseases (1)  ·  Hemic and Lymphatic Diseases (1)  ·  Immune System Diseases (1)  ·  Leukemia (1)  ·  Leukemia, Myeloid (1)  ·  Leukemia, Myeloid, Acute (1)  ·  Neoplasms (1)  ·  Neoplasms by Histologic Type (1)

Interventions

Lapatinib (1)  ·  Topotecan (1)

Sponsors

AHS Cancer Control Alberta (1)  ·  Centre Francois Baclesse (1)  ·  Shanghai Jiao Tong University School of Medicine (1)

Countries

Canada (1)  ·  China (1)  ·  France (1)

Top investigators

JIong HU, M.D. (1)  ·  Jan Storek, MD (1)